Previous 10 | Next 10 |
home / stock / gikly / gikly news
BARCELONA, Spain , May 7, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced that it has received FDA approval for the Pr...
BARCELONA, Spain , April 28, 2020 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of a new 3-mL (900-IU) vial for HyperRAB (rabies immune globulin [human]), a treatment for rabies postexposure prop...
BARCELONA, Spain , April 20, 2020 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company with a track record of more than 100 years and a recognized leader in the development and production of plasma-derived medicines, today announced it has begun iden...
BARCELONA, Spain , April 6, 2020 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2019 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 6, 2020 . Grifols' Annual Report on...
BARCELONA, Spain , Feb. 13, 2020 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announced that its PharmacyKeeper Verif...
BARCELONA , Dec. 12, 2019 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest immunoglobulin (IG) innovation, XEMBIFY ® (immune globulin subcutaneous human-klhw), the compa...
BARCELONA, Spain , Dec. 5, 2019 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announced the launch of its l...
BARCELONA, Spain , Nov. 7, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, has now introduced AlphaID™, a new, simple cheek swab that can...
- ART enables greater workflow efficiency and lean sample management, supporting laboratories' path towards total automation - The Procleix Panther System featuring ART improves system usability, increases operator walk-away time, and allows laboratories to select efficient configurati...
BARCELONA, Spain , June 19, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL™ fibrin sealant will be the first product it will...
News, Short Squeeze, Breakout and More Instantly...
Grifols SA Barcelona ADR Company Name:
GIKLY Stock Symbol:
OTCMKTS Market:
Grifols SA Barcelona ADR Website:
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Grifols To Contact Him Directly To Discuss Their Options If you suffered significant losses in Grifols stock or options and would like to discuss your legal rights, call Faruqi & Faruq...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Grifols To Contact Him Directly To Discuss Their Options If you suffered significant losses in Grifols stock or options and would like to discuss your legal rights, call Faruqi & Faruq...
Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma - The new Biomat USA plasma donor center, located at UMass Chan Medical School campus in Worcester, Mass., is Grifols' first donor center in the state and secon...